Collaborative insights from Roundtable participants highlight the future of digital pathology and AI in MASH clinical development
San Diego, February 1, 2024 — ProSciento, Inc., a leading clinical research organization specializing in metabolic diseases and the managing body of the Metabolic Continuum Roundtable, is pleased to announce the publication of a collaborative journal article authored by contributors of the Roundtable. The article, titled “Artificial Intelligence-Assisted Digital Pathology for Non-Alcoholic Steatohepatitis: Current Status and Future Directions,” appears in the February 2024 issue (Volume 80, Issue 2) of the Journal of Hepatology and is available online via DOI: 10.1016/j.jhep.2023.10.015.
The article’s co-authors include esteemed experts across hepatology, pathology, clinical research, and digital health innovation: Vlad Ratziu, Marcus Hompesch, Mathieu Petitjean, Cindy Serdjebi, Janani Iyer, Anil Parwani, Dean Tai, Elisabetta Bugianesi, Kenneth Cusi, Scott L. Friedman, Eric Lawitz, Manuel Romero-Gómez, Detlef Schuppan, Rohit Loomba, Valérie Paradis, Cynthia Behling, and Arun J. Sanyal.
The manuscript emerged from in-depth discussions during the Metabolic Continuum Roundtable’s annual forum, which ProSciento manages as part of its broader commitment to advancing scientific dialogue across the metabolic disease spectrum. The article provides a comprehensive review of the challenges in histological assessment of metabolic dysfunction-associated steatohepatitis (MASH)—previously named non-alcoholic steatohepatitis (NASH)—and explores how AI-assisted digital pathology (DP/AI) tools may revolutionize clinical trial design and therapeutic development.
With MASH prevalence rising globally—and in the absence of approved therapeutics—accurate and consistent histological assessment remains a critical component of drug development. However, current pathology methods face limitations, including sample heterogeneity and reader variability. The article explores how digital pathology workflows integrated with artificial intelligence offer a promising solution to improve accuracy, reproducibility, and efficiency in MASH clinical trials.
The review details:
- The current landscape of DP/AI tools in development for MASH
- Regulatory considerations for digital pathology applications
- The impact of automation and quantification on clinical endpoints and trial outcomes
“This publication reflects the collaborative spirit and scientific depth that define the Metabolic Continuum Roundtable,” said Dr. Marcus Hompesch, CEO of ProSciento and a contributing author. “It underscores the vital role of cross-disciplinary innovation in overcoming challenges in MASH research and shaping the future of drug development.”
For more information and to view the article abstract, visit the Journal of Hepatology website at: www.journal-of-hepatology.eu/article/S0168-8278(23)05182-6/fulltext.
To learn more about the Metabolic Continuum Roundtable, visit: www.metabolic-continuum-roundtable.com
For more about ProSciento’s research leadership, visit: www.prosciento.com